Eligi
Med
Ensayos clínicos
Suscripción
Sobre EligiMed
Ensayos Clínicos | EligiMed
Ensayos clínicos
8.676 ensayos encontrados
Terminado
Fase 3
ClinicalTrials.gov
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial to Evaluate the Safety and Efficacy of Eculizumab in Patients With Relapsing Neuromyelitis Optica (NMO)
INTERVENTIONAL
Inicio: 11 de abr de 2014
ID: NCT01892345
Completado
Fase 2
ClinicalTrials.gov
A Phase 2B, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of Once-Daily Orally Administered PH-797804 For 12 Weeks In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD) On A Background Of Tiotropium Bromide
INTERVENTIONAL
Inicio: 1 de abr de 2012
ID: NCT01543919
Completado
Fase 3
ClinicalTrials.gov
A PHASE 3, MULTICENTER, MULTINATIONAL, RANDOMIZED, OPEN-LABEL, PARALLEL-ARM STUDY OF AVELUMAB (MSB0010718C) PLUS BEST SUPPORTIVE CARE VERSUS BEST SUPPORTIVE CARE ALONE AS A MAINTENANCE TREATMENT IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER WHOSE DISEASE DID NOT PROGRESS AFTER COMPLETION OF FIRST-LINE PLATINUM-CONTAINING CHEMOTHERAPY
INTERVENTIONAL
Inicio: 25 de abr de 2016
ID: NCT02603432
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With Established Cardiovascular Disease
INTERVENTIONAL
Inicio: 12 de dic de 2019
ID: NCT04023552
Reclutando
Fase 3
ClinicalTrials.gov
A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF PF-06821497 (MEVROMETOSTAT) WITH ENZALUTAMIDE IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MEVPRO-2)
INTERVENTIONAL
Inicio: 22 de oct de 2024
ID: NCT06629779
Completado
Fase 3
ClinicalTrials.gov
A PHASE 3, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS (RSV) PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY
INTERVENTIONAL
Inicio: 17 de jun de 2020
ID: NCT04424316
Reclutando
Fase 3
ClinicalTrials.gov
AN OPEN-LABEL STUDY IN PEDIATRIC (<18 YEARS OF AGE), SEVERE HEMOPHILIA A PARTICIPANTS (COAGULATION FACTOR ACTIVITY <1%) WITH OR WITHOUT INHIBITORS OR MODERATELY SEVERE TO SEVERE HEMOPHILIA B PARTICIPANTS (COAGULATION FACTOR ACTIVITY =2%) WITH OR WITHOUT INHIBITORS COMPARING 12 MONTHS OF HISTORICAL STANDARD TREATMENT TO MARSTACIMAB PROPHYLAXIS
INTERVENTIONAL
Inicio: 9 de dic de 2022
ID: NCT05611801
Terminado
Fase 3
ClinicalTrials.gov
A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination With Aflibercept, Compared With Aflibercept Alone, in Participants With nAMD
INTERVENTIONAL
Inicio: 12 de mar de 2021
ID: NCT04757636
Terminado
Fase 3
ClinicalTrials.gov
A 2-treatment Period, Randomized, Placebo-controlled, Multicenter Parallel-group Study to Assess the Safety of QAW039 When Added to Existing Asthma Therapy in GINA Steps 3, 4 and 5 Patients With Uncontrolled Asthma.
INTERVENTIONAL
Inicio: 21 de mar de 2017
ID: NCT03052517
Completado
Fase 2
ClinicalTrials.gov
A PHASE 2B, RANDOMIZED, PLACEBO-CONTROLLED, OBSERVER-BLINDED TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE IN PREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE AND THEIR INFANTS
INTERVENTIONAL
Inicio: 7 de ago de 2019
ID: NCT04032093
Completado
Fase 2
ClinicalTrials.gov
A Placebo-controlled, Patient and Investigator Blinded, Randomized Parallel Cohort Study to Assess Pharmacodynamics, Pharmacokinetics, Safety, Tolerability and Preliminary Clinical Efficacy of VAY736 and CFZ533 in Patients With Systemic Lupus Erythematosus (SLE)
INTERVENTIONAL
Inicio: 19 de dic de 2018
ID: NCT03656562
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Obexelimab in Patients With IgG4-Related Disease (INDIGO)
INTERVENTIONAL
Inicio: 9 de ene de 2023
ID: NCT05662241
Completado
Fase 2
ClinicalTrials.gov
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 2b Dose-finding Study to Investigate the Efficacy and Safety of Ligelizumab (QGE031) in Adolescent Patients With Chronic Spontaneous Urticaria (CSU)
INTERVENTIONAL
Inicio: 1 de ago de 2018
ID: NCT03437278
Terminado
Fase 3
ClinicalTrials.gov
A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With nAMD
INTERVENTIONAL
Inicio: 12 de mar de 2021
ID: NCT04757610
Completado
Fase 3
ClinicalTrials.gov
A Randomized, Double-blind, Double-dummy, Parallel-group Study Comparing the Efficacy and Safety of Ofatumumab Versus Teriflunomide in Patients With Relapsing Multiple Sclerosis.
INTERVENTIONAL
Inicio: 26 de ago de 2016
ID: NCT02792231
Completado
Fase 2
ClinicalTrials.gov
A Prospective International Multicenter Phase II Study to Evaluate the Efficacy, Safety and Quality of Life of Pazopanib in Patients With Advanced and/or Metastatic Renal Cell Carcinoma After Previous Therapy With Checkpoint Inhibitor Treatment
INTERVENTIONAL
Inicio: 14 de nov de 2017
ID: NCT03200717
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase 3, Multi-center, Randomized, Quadruple-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis (gMG)
INTERVENTIONAL
Inicio: 27 de jun de 2022
ID: NCT05403541
Reclutando
Fase 3
ClinicalTrials.gov
A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF PF-06821497 (MEVROMETOSTAT) IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE (MEVPRO-1)
INTERVENTIONAL
Inicio: 21 de oct de 2024
ID: NCT06551324
Terminado
Fase 3
ClinicalTrials.gov
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate Cardiovascular Outcomes of TAK-875, 50 mg in Addition to Standard of Care in Subjects With Type 2 Diabetes and With Cardiovascular Disease or Multiple Risk Factors for Cardiovascular Events
INTERVENTIONAL
Inicio: 1 de jun de 2012
ID: NCT01609582
Completado
Fase 3
ClinicalTrials.gov
A PHASE 1/2/3, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND, DOSE-FINDING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, IMMUNOGENICITY, AND EFFICACY OF SARS-COV-2 RNA VACCINE CANDIDATES AGAINST COVID-19 IN HEALTHY INDIVIDUALS
INTERVENTIONAL
Inicio: 29 de abr de 2020
ID: NCT04368728
Anterior
1
...
8
9
10
...
434
Siguiente
Filtros